Before advancing investment, pilots or scale, buyer-specific economics and clinical operating evidence must justify the next commercialization step. InteliGems combined clinical beta results, site-specific ROI models and staged decision gates for a national orthopedic manufacturer, producing a $1.86M modeled net impact across 1,407 episodes as the primary proof of that test.
Modeled $1.86M net impact across 1,407 episodes, supported by achieved 75–83% exercise adherence and a 30% reduction in postoperative PT visits.
01 · Business Challenge
Bundled Risk Made Buyer Economics the Commercialization Problem
Buyers needed economic proof, clinical workflow fit and compelling evidence to align internal financial, clinical, IT and procurement decision makers.
View market condition and evidence thresholds
02 · Mandate
Prove the Business Case Before Advancing the Next Gate
Leadership needed enough economic, clinical and operating evidence to decide whether the platform should advance to the next commercialization gate before further investment or enterprise deployment.
Mandate Criteria & Commercialization Pillars
03 · Work Addressed
Five Workstreams Connected Discovery to Executive Decision Gates
InteliGems led five workstreams.
View workstreams
04 · Accountable Review
Executive and Board Review Preserved Client Authority at Each Commercial Gate
Evidence did not convert into an automatic go decision. Executive team, CEO and board review governed whether the client advanced, refined, piloted or stopped, preserving client authority over each commitment.
SWIPE →
05 · Operating Insight
Clinical Evidence Needed a Physician Champion to Become a Buying Decision
Commercialization required more than evidence. The buyer needed a defensible economic case, stakeholders willing to operationalize the solution in clinical workflows, and an internal physician champion capable of carrying the decision across finance, clinical, IT, procurement and executive decision-makers.
OPERATING INSIGHT 01 · ECONOMIC ALIGNMENT
Align episode savings with practice-side economics.
The model paired hospital episode savings with practice-side value instead of assuming one stakeholder captured all value.
OPERATING INSIGHT 02 · DATA TO ACTION
Turn recovery data into assigned clinical action.
The operating design assigned review ownership, alert thresholds and coordinator response so monitoring produced accountable action.
06 · Evidence & Results
Buyer-Specific Economics Established the Value Case
The $1.86M modeled net impact was the Primary Proof. Achieved beta adherence and fewer postoperative PT visits supported the clinical thesis as separate evidence classes.
$1.86M
Modeled net impact
PRIMARY PROOF · MODELED · 350% NET ROI · 1,407 EPISODES
75–83%
Patient exercise adherence
SUPPORTING EVIDENCE · ACHIEVED CLINICAL BETA
−30%
Post-op PT visits
SUPPORTING EVIDENCE · ACHIEVED CLINICAL BETA
View modeled financial bridge and assumptions
View evidence classification and supporting measures
The Operating Mechanics & Care Path Flow That Supported the Modeled Value Case
How InteliGems connected physical therapy workflows, automated CPT 97750 testing reports into the EMR, and de-risked enterprise purchasing gates across 25+ health systems.
Clinical Operating Model
Competitive & Reimbursement Context
Decision Tools & Board Scenarios
Enterprise Buying-Cycle Evidence
08 · Executive Relevance
Advance Only When Economics and Clinical Operations Justify the Next Commercialization Step
01 · Economic Proof
Does the buyer-specific value case withstand local assumptions?
02 · Operating Ownership
Who acts on the evidence, and what changes in workflow?
03 · Decision Gate
Is the evidence sufficient to pilot, invest, scale, redesign or stop?
View the full six-principle executive playbook
Related work
GO-TO-MARKET
MEDICAL DEVICES
Pick the First Civilian Market Before More Capital and Filings
Commercialization under uncertainty: Military-tested IV platform, many plausible civilian markets, no clear beachhead. Compressed validation cycles to 30 days across 10 market segments and anchored a $498M promising market. Validate which buyers will adopt, preserve capital for regulatory filings.
Results:
Rapid Go/No Go | 90 → 30 day validation
AI STRATEGY & OPERATING MODEL
GROWTH · COMMERCIALIZATION
Rebuild a $1M License Case the CFO Could Test
A $1M+ license rested on ~$300K of emergency dept. avoidance value. Four pathways expanded the modeled case to $1M–$5M+ a year with a value model tool so buyer executives could test local assumptions. The results opened doors for deeper enterprise sales conversations.
Results:
2–3x modeled ROI expansion
PROGRAM, PRODUCT & WORKFLOW LEADERSHIP
HEALTHCARE & MEDICAL DEVICES
Patient Workflow Transformation
Field research across five sites shifted the decision from digitizing every interaction to where digital change justified the interaction cost.
Results:
5-site field research changed the rollout decision | Digitize selectively, not every clinical interaction